Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CD49d governs immune synapse formation through actin rearrangements and synchronizes BCR signaling in CLL.

Blood·2026

Same author

CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma.

International journal of molecular sciences·2025

Same author

Targeting mutated KRAS by HLA-A*02:01 restricted anti-KRAS TCR-mimic CAR and bispecific T cell engager.

Journal of molecular medicine (Berlin, Germany)·2025

Same author

The cytoskeletal control of B cell receptor and integrin signaling in normal B cells and chronic lymphocytic leukemia.

FEBS letters·2025

Same author

Rap1 Guanosine Triphosphate Hydrolase (GTPase) Regulates Shear Stress-Mediated Adhesion of Mesenchymal Stromal Cells.

Biology·2025

Same author

A Novel In Vitro Model of the Bone Marrow Microenvironment in Acute Myeloid Leukemia Identifies CD44 and Focal Adhesion Kinase as Therapeutic Targets to Reverse Cell Adhesion-Mediated Drug Resistance.

Cancers·2025

Search research articles

Related Experiment Video

Updated: Mar 17, 2026

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

Memory programming and new manufacturing paradigms in CAR-T cell therapy.

Niloufar Mohammadkhani^1,2, Saber Ebrahimi^3,4, Marzieh Hesam Mohammadi^1,2

¹Department of Medicine I, Medical Center-University of Freiburg and Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.

Cancer Gene Therapy

|March 16, 2026

Summary

Strategies to enhance chimeric antigen receptor (CAR) T cell persistence are explored, balancing anti-tumor activity with potential toxicities. Emerging "off-the-shelf" CAR-T therapies may reduce the need for prolonged CAR-T cell survival.

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Related Experiment Videos

Last Updated: Mar 17, 2026

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Area of Science:

Immunology
Cell Therapy
Oncology

Background:

Chimeric antigen receptor (CAR) T cell therapy shows promise but is limited by short in vivo persistence.
Strategies focus on enhancing CAR-T cell survival, often via memory phenotypes, to improve anti-tumor activity.

Purpose of the Study:

To review recent advances in augmenting CAR-T cell persistence.
To discuss the role of memory-associated features in CAR-T cell longevity.
To highlight emerging "off-the-shelf" CAR-T platforms and their implications for persistence engineering.

Main Methods:

Literature review of studies on CAR-T cell persistence.
Analysis of strategies leveraging memory-like phenotypes.
Evaluation of emerging "off-the-shelf" CAR-T technologies.

Main Results:

Enhanced persistence can improve anti-tumor effects but may increase toxicity.
Memory-like phenotypes are key targets for prolonging CAR-T cell survival.
Novel "off-the-shelf" platforms offer potential for broad accessibility and timely treatment.

Conclusions:

Context-specific approaches are needed for CAR-T cell persistence strategies.
The development of "off-the-shelf" CAR-T cells may decrease the emphasis on engineering enhanced persistence.
Future directions involve balancing efficacy, safety, and accessibility in CAR-T cell therapy development.